RxDoctor Payments Data

Robert Dewitt, MD

Internal Medicine · Alvin, TXNPI 1972589737

Payments from drug & device makers

$8,256in general payments, 2019–2025

Across 376 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Johnson & Johnson$807
  • Novo Nordisk$802
  • GSK$590
  • Pfizer$398
  • Boehringer Ingelheim$395
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$8,19599%
  • Education$611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,256 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$243,484
Medicare patients
341
Services billed
3,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide134$157,568
EliquisApixaban144$138,066
MounjaroTirzepatide49$65,374
XareltoRivaroxaban65$58,724
JardianceEmpagliflozin63$57,786
FarxigaDapagliflozin Propanediol65$55,568
MyrbetriqMirabegron45$36,691
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$35,432
TrulicityDulaglutide17$28,780
RybelsusSemaglutide16$27,681
Tresiba Flextouch U-100Insulin Degludec53$27,240
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$23,410
JanuviaSitagliptin Phosphate14$21,120
SymbicortBudesonide/Formoterol Fumarate49$20,095
Tresiba Flextouch U-200Insulin Degludec13$19,371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$802$185,249150 claims
PfizerEliquis, Premarin$398$145,663163 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta$1,523$115,365167 claims
Lilly USA, LLCMounjaro, Trulicity$350$94,15466 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$395$77,50491 claims
Johnson & JohnsonXarelto$807$58,72465 claims
GSKTrelegy Ellipta, Anoro Ellipta$590$53,44278 claims
MerckJanuvia, Janumet$163$39,24729 claims
Astellas Pharma US IncMyrbetriq$327$36,69145 claims
NovartisEntresto$270$13,14220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Alvin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →